Side-by-side · Research reference

MazdutidevsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED19/62 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

Mazdutide

Teriparatide

Primary target

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

Yes — physiological receptor-mediated signaling preserved

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

Mazdutide

Teriparatide

Phase 2 studied dose

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

—

Frequency

Once weeklyJi 2026 Luo 2026

Once daily

Intermittent administration preserves anabolic effect.

Route

SubcutaneousJi 2026

Subcutaneous (thigh or abdomen)

Dose escalation

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

—

Evidence basis

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

RCT / FDA-approved

Duration (trials)

24–48 weeks

—

Population

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

—

Phase 3 comparator

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

—

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Timing

—

Morning or evening (flexible)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

Mazdutide

Teriparatide

Percentage body weight loss

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

—

Absolute weight loss

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

—

Responder rate (≥10% loss)

Not explicitly reported in available abstracts

—

Mechanism

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

—

BMI reduction

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

—

Visceral fat

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

—

Glycemic improvement

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

—

Comparator efficacy

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

—

Key publications

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

—

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

Mazdutide

Teriparatide

Gastrointestinal symptoms

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

—

Injection site reactions

Erythema, pruritus, local discomfort

—

Hypoglycemia

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

—

Cardiovascular effects

Increased heart rate (glucagon effect, transient)

—

Pancreatitis risk

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

—

Thyroid C-cell tumors

Black box warning for GLP-1 class (rodent data); human relevance unclear

—

Gallbladder disease

Cholelithiasis, cholecystitis (rapid weight loss effect)

—

Tolerability

Generally well-tolerated; GI effects diminish with dose titration

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

Mazdutide

Teriparatide

1. Preparation

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Injection site

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Timing

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Storage

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Needle technique

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.